In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass dive into Novartis' (NVS 0.53%) recent earnings report, to give investors the key takeaways from the company this quarter.
The guys discuss how earnings were largely in line with expectations and note how the company's recent deal to acquire GlaxoSmithKline's (GSK 0.10%) early-stage oncology business while divesting itself of its vaccines business has made Novartis a more focused company. While David isn't terribly excited about the stock at the moment, the addition of this business to Novartis' own early stage oncology assets means that David does see the potential for outperformance here in the long run, for investors who are willing to wait.
